Sarepta Therapeutics, Inc.
SRPT
$20.55
$0.080.39%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.41B | 2.48B | 2.23B | 1.90B | 1.64B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.41B | 2.48B | 2.23B | 1.90B | 1.64B |
| Cost of Revenue | 1.97B | 1.92B | 1.78B | 1.12B | 1.03B |
| Gross Profit | 443.83M | 565.14M | 449.69M | 778.36M | 609.29M |
| SG&A Expenses | 527.29M | 563.60M | 564.50M | 557.87M | 525.70M |
| Depreciation & Amortization | 2.55M | 2.47M | 2.41M | 2.41M | 2.57M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.50B | 2.48B | 2.35B | 1.68B | 1.56B |
| Operating Income | -86.01M | -932.00K | -117.21M | 218.08M | 81.03M |
| Income Before Tax | -252.19M | -24.13M | -164.19M | 260.77M | 129.40M |
| Income Tax Expenses | 19.33M | 33.83M | 84.20M | 25.54M | 7.56M |
| Earnings from Continuing Operations | -271.51 | -57.96 | -248.39 | 235.24 | 121.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -271.51M | -57.96M | -248.39M | 235.24M | 121.85M |
| EBIT | -86.01M | -932.00K | -117.21M | 218.08M | 81.03M |
| EBITDA | -36.28M | 40.15M | -78.25M | 255.81M | 119.67M |
| EPS Basic | -2.73 | -0.58 | -2.52 | 2.46 | 1.29 |
| Normalized Basic EPS | -0.49 | 0.07 | -0.65 | 1.50 | 0.62 |
| EPS Diluted | -2.90 | -0.76 | -2.58 | 2.39 | 1.24 |
| Normalized Diluted EPS | -0.67 | -0.12 | -0.78 | 1.35 | 0.59 |
| Average Basic Shares Outstanding | 391.89M | 387.04M | 383.65M | 380.28M | 377.62M |
| Average Diluted Shares Outstanding | 412.70M | 412.91M | 405.43M | 407.18M | 395.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |